ClearPoint Neuro, Inc.
HealthcareNASDAQ:CLPT · NASDAQ Capital Market
-$0.40 today
Vol 0.44M · Avg 0.59M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-91.1%
avg 19.3%
ROIC
-27.6%
avg -67.5%
ROA
-26.1%
avg -51.8%
Analysis
ROA is currently the strongest return metric at -26.1% versus its period average of -51.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Joseph Michael Burnett | President, Chief Executive Officer & Director | $1.01M | — | 49 | $116,842.00 | 0.39% |
Danilo D'Alessandro | Chief Financial Officer | $554,360.00 | — | 41 | $119,285.00 | 0.40% |
Jeremy Stigall | Chief Business Officer | $522,809.00 | — | 42 | $123,633.00 | 0.41% |
Robert C. Korn | Senior Vice President of Sales & Business Development | $305,123.00 | — | 61 | $200,000.00 | 0.67% |
Mazin Sabra | Chief Operating Officer | — | — | 46 | $80,624.00 | 0.27% |
Ellisa Cholapranee | General Counsel & Secretary | — | — | — | — | — |
Mary McNamara-Cullinane | Senior Vice President of Regulatory Affairs | — | — | — | — | — |
Megan Faulkenberry | Senior Vice President of Quality | — | — | — | — | — |
Paul S. Larson FAANS | Chief Medical Officer | — | — | — | $144,622.00 | 0.48% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
10
$1.69M
Net Sentiment
$1.69M
Net selling
Most Active
BURNETT JOSEPH
7 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 10 sells worth $1.69M over the last 12 months. That adds up to net selling of $1.69M. BURNETT JOSEPH was the most active insider with 7 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -3.2% | +23.5% (14yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -3.2% over three years. Forward estimates point to Revenue at +23.5% (14yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Avanos Medical, Inc.
NYSE:AVNS
$1.17B
COMPASS Pathways plc
NASDAQ:CMPS
$1.16B
SI-BONE, Inc.
NASDAQ:SIBN
$683.87M
Surmodics, Inc.
SRDX
$614.51M
Cytek Biosciences, Inc.
NASDAQ:CTKB
$511.40M
Varex Imaging Corporation
NASDAQ:VREX
$464.78M
Orthofix Medical Inc.
NASDAQ:OFIX
$376.33M
SNDL Inc.
NASDAQ:SNDL
$369.44M
Standard BioTools Inc.
NASDAQ:LAB
$346.53M
Akebia Therapeutics, Inc.
NASDAQ:AKBA
$248.00M
Who manages CLPT?
ClearPoint Neuro, Inc. (CLPT) lists 9 active executives. The top listed executive is Danilo D'Alessandro, Chief Financial Officer.
Are CLPT insiders buying or selling?
Recent insider activity shows net selling of $5.53M.
Explore More
Continue the stock analysis
Jump to another research area for this company.